Panthenol

Panthenol (Provitamin B5): A Comprehensive Reference

1. Identity: Chemical Names, Forms, and Natural Sources

Panthenol (also called pantothenol) is the alcohol analog of pantothenic acid (vitamin B5), and is thus a provitamin of B5. It is structurally similar to vitamin B5 except that it contains a hydroxyl group, making it an alcohol. Its molecular mass is 205.3 g/mol.

Panthenol comes in two enantiomers: D and L. Only D-panthenol (dexpanthenol) is biologically active. For cosmetic use, panthenol comes either in D form or as a racemic mixture of D and L (DL-panthenol). The CAS numbers are 81-13-0 (DL) and 16485-10-2 (D form). The IUPAC name is butanamide, 2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethyl-, (2R)-.

Common synonyms and designations: The compound is commonly known as Provitamin B5, D-panthenol, dexpanthenol, pantothenol, and D-pantothenyl alcohol. The INCI (International Nomenclature of Cosmetic Ingredients) name used on product labels is simply Panthenol.

Physical form: It is an odorless, transparent, highly viscous, and colorless liquid at room temperature. It is a stable, water-soluble, light ingredient that readily penetrates the skin. It is soluble in water, ethanol, methanol, and propylene glycol, and insoluble in fats. It is stable in the pH range from 4.0 to 7.5, with an optimum pH of 6.0.

Natural occurrence and commercial source: Small quantities of pantothenic acid are found in nearly every food, with high amounts in whole grain cereals, legumes, eggs, meat, and royal jelly. A particularly rich natural source is royal jelly obtainable from honey bee colonies. However, panthenol itself as used commercially is synthetic. The extraction/synthesis process involves a combination of propanolamine and beta-dimethylbutyrolactone, and the ingredient as used in formulations is synthetic in origin. Pro-vitamins are similar to synthetically-designed prodrugs and can yield improved oral bioavailability of supplements: pantothenic acid (vitamin B5) is unstable, so a stable alcohol, panthenol (provitamin B5), is the parent molecule that is subsequently oxidised to the bioactive form in vivo.

Commercial scale: The current world demand for R-pantothenate and R-panthenol is more than 10,000 and 2,000 tonnes respectively.

Common dosage forms and preparations: Routes of administration include topical (creams, ointments), oral, and intramuscular (IM) or intravenous (IV) injection. Panthenol is found in lotions, ointments, nasal sprays, eye drops, and cleaning solutions for contact lenses. Calcium pantothenate is the most commonly used form of supplemental pantothenic acid for oral administration. Dexpanthenol (also called D-pantothenyl alcohol or D-panthenol) is the most commonly used injectable form of pantothenic acid. Dietary supplements of pantothenic acid commonly use pantothenol (or panthenol), a shelf-stable analog, which is converted to pantothenic acid once consumed.

2. Historical Background and Discovery

The name pantothenic acid is derived from the Greek pantothen, meaning "from all sides" or "everywhere." The vitamin was first isolated in 1931, and its role as an essential component in the growth of yeast cells was demonstrated in 1933. The involvement of pantothenic acid in coenzyme A and cellular metabolism was elucidated in the late 1940s and early 1950s. Knowledge of pantothenic acid resulted from experimentation on microorganisms and chicks.

The essential nature of pantothenic acid was discovered by Roger J. Williams in 1933 by showing it was required for the growth of yeast. Three years later, Elvehjem and Jukes demonstrated that it was a growth and anti-dermatitis factor in chickens.

In the mid-1960s, pantothenic acid was identified as a component of an acyl carrier protein (ACP) in the fatty acid synthesis complex. Fritz Albert Lipmann won the Nobel Prize in Physiology and Medicine "for his discovery of coenzyme A and its importance for intermediary metabolism."

Traditional and historical use: Panthenol as a distinct isolated chemical entity has no pre-modern traditional use; however, pantothenic acid has always been consumed as part of a broad diet. Mouse models identifying skin irritation and loss of hair color as possible results of severe pantothenic acid deficiency prompted the cosmetic industry to begin adding pantothenic acid to various cosmetic products including shampoo, though these products showed no benefits in human trials. Despite this, many cosmetic products still advertise pantothenic acid additives. The clinical use of dexpanthenol as a topical wound-healing and mucosal agent in European pharmaceutical practice dates at least to the 1960s: dexpanthenol has been available as a nasal ointment without preservatives (Bepanthen® Roche Eye and Nose Ointment) since the 1960s.

3. Key Constituents and Active Compounds

Panthenol is itself the single active molecular entity of relevance in this context. Its biological activity is entirely contingent on its conversion to pantothenic acid and the downstream formation of coenzyme A (CoA). The key biochemical relationships are as follows:

• Conversion to pantothenic acid: Panthenol is the alcohol analog of pantothenic acid (vitamin B5) and is thus a provitamin of B5. In organisms, it is quickly oxidized to pantothenic acid. Panthenol readily penetrates into the skin and mucous membranes (including the intestinal mucosa), where it is quickly oxidized to pantothenic acid.
• Coenzyme A (CoA) synthesis: In cells, pantothenic acid is mainly used for the biosynthesis of coenzyme A (CoA) and acyl carrier protein (ACP). These coenzymes are important for all cells and are involved in over 100 different intermediate reactions in cellular metabolism. In cells, phosphorylation of pantothenic acid to generate phosphopantothenic acid by the pantothenate kinase enzymes is the first step in coenzyme A synthesis.
• Coenzyme A functions: Coenzyme A, the physiologically active form of pantothenic acid, serves as a cofactor for a variety of enzyme-catalyzed reactions involving transfer of acetyl (two-carbon) groups; the precursor fragments of various lengths are bound to the sulfhydryl group of coenzyme A. CoA and its acetylated metabolite, acetyl-CoA, are key factors in several cellular processes, including energy metabolism, autophagy, and mitosis, acting as a central metabolic intermediate and as signal transducers in anabolic and catabolic reactions.
• Acyl carrier protein (ACP): Pantothenic acid (pantothenate) is a precursor of coenzyme A (CoA) and the acyl carrier protein (ACP) that play essential roles in fatty acid metabolism.
• Hygroscopicity: Pantothenic acid is extremely hygroscopic. This physical property underlies panthenol's role as a humectant in topical formulations, as the pantothenic acid produced after absorption draws water into tissues.
• Distribution in the body after absorption: Dexpanthenol is readily converted to pantothenic acid, which is widely distributed into body tissues, mainly as coenzyme A. Highest concentrations are found in the liver, adrenal glands, heart, and kidneys.

4. Established Mechanisms of Action

4.1 Humectancy and Stratum Corneum Hydration

The topical use of dexpanthenol, the stable alcoholic analog of pantothenic acid, is based on good skin penetration and high local concentrations when administered in an adequate vehicle, such as water-in-oil emulsions. Topical dexpanthenol acts like a moisturizer, improving stratum corneum hydration, reducing transepidermal water loss, and maintaining skin softness and elasticity.

4.2 Skin Penetration

Panthenol, a hydrophilic compound with low molecular weight, readily diffuses through the stratum corneum, the outermost layer of the skin, facilitating delivery to deeper epidermal layers. This penetration is enhanced by its interaction with the lipid matrix of the intercellular lamellae, allowing it to reach viable skin cells without significant barrier disruption.

4.3 Fibroblast Proliferation and Wound Healing

Activation of fibroblast proliferation, which is of relevance in wound healing, has been observed both in vitro and in vivo with dexpanthenol. Pantothenic acid is essential to normal epithelial function. Dexpanthenol is an active ingredient that promotes wound healing. It is converted in vivo to pantothenic acid, a component of coenzyme A, which in turn activates fibroblast proliferation and accelerates the reepithelialization process.

At the cellular level, panthenol stimulates mitosis and proliferation in fibroblasts and keratinocytes, key cells involved in skin repair and regeneration. It inhibits pro-inflammatory mediators such as interleukin-6 and prostaglandin E2, while its antioxidant properties neutralize reactive oxygen species generated during injury.

D-panthenol was reported to facilitate wound repair by up-regulating wound-healing-associated molecules, such as IL-6, IL-1β, CYP1B1, CXCL1, CCL18, and KAP4-2.

4.4 Skin Barrier Repair

Panthenol can promote skin barrier repair by enhancing lipid synthesis and epidermal differentiation. In skin-care products, it helps to keep the skin moist and supple, stimulates cell growth and tissue repair, and inhibits inflammation and reddening.

4.5 Anti-Inflammatory Activity

Pantothenic acid plays an important role in both anti-inflammatory and proinflammatory events, due to its importance in regulating the cytokine pathway. At the molecular level, downstream activity via CoA supports both pro-repair and inflammation-modulating pathways. Topically, the anti-inflammatory effects have been demonstrated experimentally, as reviewed in the peer-reviewed literature.

4.6 Antimicrobial Activity

Pantothenol has been shown to markedly inhibit the phosphorylation activity of the prokaryotic type II pantothenate kinase of Staphylococcus aureus, which catalyzes the first step of the coenzyme A biosynthetic pathway. Since type II enzymes are found exclusively in staphylococci, pantothenol suppresses the growth of S. aureus, S. epidermidis, and S. saprophyticus, which inhabit the skin of humans. Therefore, the addition of this provitamin to ointment and skincare products may be highly effective in preventing infections by opportunistic pathogens.

4.7 Nail Hydration

Panthenol can substantially increase the water storage capacity of nails, and by this mechanism the flexibility and stability of nails are improved.

5. Scientific Evidence by Area of Use

5.1 Wound Healing

Evidence strength: Moderate (multiple clinical trials, consistent positive direction, but most trials are small).

A systematic literature search in the PubMed and Embase databases querying terms including dexpanthenol, panthenol, superficial wound, minor wound, wound healing, skin repair, and postprocedure identified 33 publications; of these, 8 articles were of relevance for assessing the usefulness of topical dexpanthenol in wound healing after medical and cosmetic interventions.

In vitro and clinical studies provided evidence that topically applied dexpanthenol promotes superficial and postprocedure wound healing. The latest findings confirmed that dexpanthenol upregulates genes that are critical for the healing process.

One of the more robust individual trials within this body of evidence was described as follows: Girard et al. conducted a double-blind, intra-individual comparative trial that studied the postprocedure wound healing effects of an ointment containing 5% dexpanthenol. In total, 35 patients received an autologous skin graft because of burns. For 14 days, the dexpanthenol-containing formulation or vehicle was topically applied to the mesh graft donor sites (i.e., to sites from which skin grafts were removed). These superficial wounds tended to heal more rapidly at the sites treated with dexpanthenol than at the skin areas treated with vehicle, as assessed clinically and by measurements of microcirculation, temperature, and biomechanical properties. During the second week of the study, the skin areas topically treated with dexpanthenol were more hydrated than those treated with vehicle (p = 0.05) based on clinical scores.

In double-blind, placebo-controlled clinical trials, dexpanthenol was evaluated for its efficacy in improving wound healing. Epidermal wounds treated with dexpanthenol emulsion showed a reduction in erythema, and more elastic and solid tissue regeneration. Monitoring of transepidermal water loss (TEWL) showed a significant acceleration of epidermal regeneration as a result of dexpanthenol therapy, as compared with the vehicle. In an irritation model, pretreatment with dexpanthenol cream resulted in significantly less damage to the stratum corneum barrier, compared with no pretreatment.

In vivo and animal studies have been undertaken to elucidate a potential mechanism of action for the use of pantothenic acid and its derivatives for enhancing wound healing. Dexpanthenol as a pastille and as a spray has been evaluated in small clinical trials for wound healing in postoperative tonsillectomy, endotracheal intubation, and endoscopic sinus surgery. Increased hydration due to dexpanthenol may explain the positive effects, or a possible increase in the number of dermal fibroblasts.

Limitations: The existing trials are largely small, and many studies included in prior systematic searches were excluded because they investigated dexpanthenol only as part of combination products, making it difficult to isolate its singular contribution.

5.2 Skin Barrier Function and Moisturization

Evidence strength: Moderate-to-strong for topical moisturization; more preliminary for systemic skin effects.

Panthenol-containing formulations at concentrations of 1.0% and 5.0% produced significant decreases in TEWL after 30-day applications. In skin washed with sodium lauryl ether sulfate (SLES), significant reduction of TEWL was evident two hours after application of formulations loaded with panthenol, when compared with control and vehicle.

Two randomized, intra-individual comparison studies were performed in healthy subjects to evaluate the skin moisturization and barrier restoration potential of a new topical panthenol-containing emollient (NTP-CE). In Study 1 (N = 23), two skin areas — one challenged with 0.5% sodium dodecyl sulfate solution and one unchallenged — were treated with NTP-CE for 3 weeks. TEWL, skin hydration, and intercellular lipid lamellae (ICLL) organization were measured at regular intervals during the study.

A 2024 multi-center study evaluated a panthenol-enriched mask across multiple impaired-barrier skin types: the study assessed the efficacy and tolerance of a facial mask in repairing, hydrating, sebum regulation, and providing anti-inflammatory effects on various impaired skin barrier conditions. The performance of the mask on dry sensitive, oily sensitive, and oily acne skin types was evaluated through clinical assessment, objective instrumental measurements, and subjective self-assessments. The mask demonstrated strong hydrating and moisturizing properties across all three skin subgroups, with notable increases in hydration and decreases in TEWL in all skin types.

A 2025 double-blind randomized controlled study assessed a panthenol-enriched mask following facial laser treatment: prior studies have demonstrated that topical panthenol significantly improves stratum corneum hydration and accelerates epidermal barrier restoration. A split-face trial compared a moisturizer containing 5% panthenol, madecassoside, and copper-zinc-manganese to topical corticosteroids following ablative laser treatment and found superior tolerance and equivalent efficacy in reducing downtime and erythema.

5.3 Atopic Dermatitis

Evidence strength: Moderate, with consensus-level clinical recommendations.

Dexpanthenol has multiple pharmacological effects and has been employed to treat various skin disorders such as atopic dermatitis (AD). A review aimed to summarize up-to-date evidence relating to dexpanthenol and to provide a consensus on how to use it effectively for the treatment of AD. The evidence on the application and efficacy of dexpanthenol in AD was reviewed, focusing on improvement of skin barrier function, prevention of acute flares, and its topical corticosteroid (TCS) sparing effects.

Dexpanthenol was found to be effective and well-tolerated for the treatment of AD. It improves skin barrier function, reduces acute and frequent flares, has a significant TCS sparing effect, and enhances wound healing for skin lesions.

The expert panel recommended that patients with atopic dermatitis use topical corticosteroids (TCS) and dexpanthenol alternatively, especially if the disease is mild to moderate.

One study found that dexpanthenol can potentially treat mild to moderate childhood atopic dermatitis. Other research suggests that dexpanthenol cream can help manage mucocutaneous side effects during isotretinoin therapy.

In the domain of radiation-related skin damage, Schmutz et al. reported non-inferiority in maintaining TEWL scores in acute radiation dermatitis (0.1% methylprednisolone cream vs. 0.5% dexpanthenol cream). As shown in full-thickness 3D skin models representing acute radiodermatitis and mucositis, skin impairment seven days after radiotherapy demonstrated a completely restored epidermal part after treatment with dexpanthenol-containing ointment or liquid.

5.4 Nasal and Mucosal Applications

Evidence strength: Preliminary to moderate; studies are generally small, and some lack statistical significance.

A prospective, controlled, parallel-group observational study investigated the efficacy of a spray containing hyaluronic acid and dexpanthenol to optimise regular treatment after nasal cavity surgery in 49 patients with chronic rhinosinusitis. The control group received standard therapy. Mucosal regeneration was determined using rhinoscopy sum score (RSS). Mucosal regeneration achieved good final results in both groups, tending to better improvement through the spray application, without statistically significant differences during the whole assessment period. No statistically significant benefit was identified for nasal breathing, foreign body sensation, and average rhinomanometric volume flow.

Used for treatment of rhinitis sicca anterior and after nasal and sinus surgery, dexpanthenol has been available as a nasal ointment without preservatives since the 1960s. Dexpanthenol is an active ingredient that promotes wound healing. It is converted in vivo to pantothenic acid, a component of coenzyme A, which in turn activates fibroblast proliferation and accelerates the reepithelialization process. In a study by Kehrl and Sonnemann, the effect of dexpanthenol in rhinitis sicca has been scientifically verified.

5.5 Ophthalmic Use

Evidence strength: Limited; available trial results are mixed.

A prospective randomized double-blind clinical study investigated corneal wound healing after treatment either with an eye gel containing calf blood extract or an eye ointment containing vitamin A and dexpanthenol in 54 outpatients treated for corneal foreign body injury. The size of corneal lesions was measured by planimetry. Results showed the calf blood extract eye gel to be statistically more effective in promoting corneal wound healing, especially in patients with wound areas larger than 6 mm². This finding illustrates that dexpanthenol-containing ophthalmic preparations are not uniformly superior to alternatives.

5.6 Gastrointestinal Motility (Paralytic Ileus)

Evidence strength: Established clinical use, though pharmacological mechanism is incompletely characterized.

Dexpanthenol is used via injection to help restart bowel movements after surgery (postoperative ileus). Decrease in acetylcholine content in the gut would result in decreased peristalsis and, in extreme cases, adynamic ileus. Dexpanthenol, through its role in CoA synthesis and in turn acetylcholine production, is thought to support gut motility. The injectable prescribing information specifies: for prevention of post-operative adynamic ileus, 250 mg (1 mL) or 500 mg (2 mL) intramuscularly, repeated in 2 hours and then every 6 hours until all danger of adynamic ileus has passed.

5.7 Hair Health

Evidence strength: Preliminary (a small number of clinical reports and in vitro studies; few robust RCTs).

D-panthenol in shampoos, conditioners, hair and scalp treatments, and hair tonics not only improves the shine, feel, and flexibility of the hair, but also protects the hair against mechanical damage and in general makes the hair more resistant to environmental stresses.

At the cellular level, a PMC study found that: D-panthenol is a well-known cosmetic and pharmaceutical ingredient used for anti-inflammatory, skin regenerating, and stratum corneum hydrating effects. Because of these properties, D-panthenol is widely used to relieve atopic dermatitis, nappy rash symptoms, and sunburns. D-panthenol was reported to facilitate wound repair by up-regulating wound-healing-associated molecules. It has long been used for hair and scalp care products, especially for the purpose of anti-hair loss.

Several clinical studies reported that the oral administration of D-panthenol improved female pattern hair loss as well as male androgenetic alopecia. However, these reports are small in scale and have not been subject to large multicenter replication.

5.8 Acne

Evidence strength: Weak; preliminary and small-scale studies only.

Following from discoveries in mouse trials, in the late 1990s a small study was published promoting the use of pantothenic acid to treat acne vulgaris. According to a study published in 1995 by Dr. Lit-Hung Leung, high doses of vitamin B5 resolved acne and decreased pore size. Dr. Leung proposed a mechanism, stating that CoA regulates both hormones and fatty acids, and without sufficient quantities of pantothenic acid, CoA will preferentially produce androgens. This causes fatty acids to build up and be excreted through sebaceous glands, causing acne. This proposed mechanism remains speculative, and the original study was small and methodologically limited.

6. Body Systems and Health Areas of Association

• Integumentary system (skin): Skin barrier function, wound healing, moisturization, atopic dermatitis, diaper rash, sunburn, radiodermatitis, acne (preliminary).
• Integumentary system (hair and nails): Hair condition, tensile strength, hair loss (preliminary clinical reports); nail hydration and flexibility.
• Mucosal tissues: Nasal mucosa (rhinitis sicca, post-surgical recovery), ocular surface (corneal healing), oral and pharyngeal mucosa.
• Gastrointestinal system: Bowel motility via acetylcholine-mediated mechanisms; indicated for paralytic ileus in injectable form.
• Metabolic / systemic: This essential vitamin participates in energy generation, synthesizing hormones, and maintaining optimal conditions for skin, hair, and nails. Coenzyme A serves as a cofactor for a variety of enzyme-catalyzed reactions that are important in the metabolism of carbohydrates, fatty acids, proteins, gluconeogenesis, sterols, steroid hormones, and porphyrins.
• Nutritional supplementation: Dexpanthenol is used as a supplement or application to support a healthy epithelium and is also used to prevent vitamin deficiency in patients receiving total parenteral nutrition (TPN).

7. Dosage Forms and Concentrations Reported in Studies

The following concentrations and doses are reported in the referenced scientific literature and prescribing information. They are presented descriptively and not as recommendations.

• Topical cosmetic/dermatological formulations: Concentrations in cosmetic products range from 0.1% to 5%. Topical application of panthenol at concentrations of 2–5% has been shown to stimulate the regeneration of injured skin. The wound healing trial by Girard et al. used an ointment containing 5% dexpanthenol.
• Nasal ointment: The dexpanthenol nasal ointment formulation contains 0.05 g dexpanthenol per gram of ointment (5%). A 1-cm long ribbon of ointment is applied to the nasal mucosa and rubbed in gently once to several times daily.
• Injectable form (for paralytic ileus): For prevention of post-operative adynamic ileus: 250 mg (1 mL) or 500 mg (2 mL) intramuscularly, repeated in 2 hours and then every 6 hours until all danger has passed.
• Oral supplementation: The amount of pantothenic acid in dietary supplement products may contain up to 1,000 mg (200 times the Adequate Intake level for adults), without evidence that such large amounts provide any benefit. The 10–25 mg found in many multivitamin supplements might improve pantothenic acid status.
• Atopic dermatitis formulations: One comparative trial referenced in the literature used 5% dexpanthenol in a water-in-oil formulation versus 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis.

8. Safety Considerations and Interactions

8.1 General Tolerability

Panthenol is generally well-tolerated. In rare cases, skin irritation causing contact dermatitis and contact allergies have been reported. Only panthenol and dexpanthenol are approved by the FDA for use in cosmetics.

8.2 Allergic Contact Dermatitis

Although rare, contact allergy is a documented and clinically meaningful safety concern: Panthenol (synonym: dexpanthenol), frequently included in moisturizers, wound-healing agents, and other cosmetics, has been shown to be responsible for allergic contact dermatitis (ACD). A retrospective review of patients patch tested between 2009 and 2017 at the Department of Dermatology of Coimbra's University Hospital identified that, among 2,171 patients, 26 (1.2%) had positive patch test reactions to dexpanthenol, mostly patients tested for chronic eczema.

Allergic contact dermatitis has been reported with topical use of dexpanthenol and panthenol cream. A meta-analysis from 1966 to 2002 recorded an adverse reaction rate of 1.4 per 100 subjects. The majority of these events were mild gastrointestinal complaints.

8.3 Oral Toxicity

The toxicities of pantothenic acid and panthenol are negligible, as no adverse reactions have been reported in any species even at large doses. In the context of oral pantothenic acid supplementation more broadly, it has been noted that pantothenic acid has no outstanding pharmacological actions when administered to experimental animals or normal humans, and the vitamin is essentially nontoxic; as much as 10 g can be given daily to humans without producing symptoms.

8.4 Rare Serious Adverse Event

A case report of a life-threatening eosinophilic pleuropericardial effusion exists with concomitant use of biotin 10 mg/day and pantothenic acid 300 mg/day. There is one report of a 76-year-old woman who developed this life-threatening condition while taking 300 mg of pantothenic acid per day and 10 mg of biotin per day. However, it is not clear whether the vitamins caused the problem.

8.5 Drug Interactions (Injectable Form)

The injectable form of dexpanthenol carries specific interaction warnings: the effects of succinylcholine appeared to have been prolonged in a woman administered dexpanthenol. Dexpanthenol may prolong bleeding time and should be used with caution in patients at risk of bleeding or with hemophilia. Reactions may occur if dexpanthenol injection is used concurrently with antibiotics, anesthetics, or barbiturates.

8.6 Contraindications (Injectable Form)

Dexpanthenol should not be injected to treat mechanical intestinal obstruction. For patients with paralytic ileus, attention must also be paid to replenishing water and electrolytes, preventing anemia, reducing blood protein, fighting infections, and avoiding drugs that reduce intestinal motility.

8.7 Renal and Hepatic Considerations

Because dexpanthenol is a water-soluble vitamin analog, it has a very wide safety margin. No formal dose adjustments are typically required for patients with mild to moderate kidney or liver issues.

8.8 No Tolerable Upper Intake Level Set

Pantothenic acid is considered to be relatively safe. In a 1998 review, the Institute of Medicine did not set a tolerable upper intake level for pantothenic acid, reflecting the lack of established dose-dependent adverse effects at nutritional doses.

References

• Wikipedia: Panthenol
• StatPearls (NCBI Bookshelf): Vitamin B5 (Pantothenic Acid)
• PMC / MDPI Pharmaceuticals: Dexpanthenol in Wound Healing after Medical and Cosmetic Interventions (Postprocedure Wound Healing) — Ebner et al., 2020
• MDPI Pharmaceuticals: Dexpanthenol in Wound Healing after Medical and Cosmetic Interventions (full text)
• PubMed: Topical Use of Dexpanthenol in Skin Disorders — Ebner et al., Am J Clin Dermatol, 2002
• Springer: Topical Use of Dexpanthenol in Skin Disorders (American Journal of Clinical Dermatology)
• PMC: Use of Dexpanthenol for Atopic Dermatitis — Benefits and Recommendations Based on Current Evidence (Cho et al., J Clin Med, 2022)
• MDPI Journal of Clinical Medicine: Use of Dexpanthenol for Atopic Dermatitis — Benefits and Recommendations Based on Current Evidence
• PMC: Dexpanthenol Promotes Cell Growth by Preventing Cell Senescence and Apoptosis in Cultured Human Hair Follicle Cells
• PMC: Antimicrobial Activity of Pantothenol against Staphylococci Possessing a Prokaryotic Type II Pantothenate Kinase
• PMC: Clinical Efficacy of a Spray Containing Hyaluronic Acid and Dexpanthenol after Surgery in the Nasal Cavity
• PMC: Tolerability and Effects on Quality of Life of Liposomal Nasal Spray Treatment Compared to Nasal Ointment Containing Dexpanthenol or Isotonic NaCl Spray in Patients with Rhinitis Sicca
• PubMed: Corneal Wound Healing after Superficial Foreign Body Injury: Vitamin A and Dexpanthenol versus a Calf Blood Extract
• PubMed: Allergic Contact Dermatitis Caused by Dexpanthenol — Probably a Frequent Allergen
• Drugs.com Natural Product Database: Pantothenic Acid Uses, Benefits & Dosage
• Drugs.com: Dexpanthenol Package Insert / Prescribing Information
• DrugBank: Dexpanthenol — Uses, Interactions, Mechanism of Action
• PubMed: Panthenol Citrate Biomaterials Accelerate Wound Healing and Restore Tissue Integrity
• Semantic Scholar: Skin Moisturizing Effects of Panthenol-Based Formulations — Camargo & Gaspar
• Wiley / Journal of Cosmetic Dermatology: Efficacy and Safety of a Panthenol-Enriched Mask for Individuals with Distinct Impaired Skin Barrier Subtypes — Zhang et al., 2024
• Wiley / Journal of Cosmetic Dermatology: Evaluation of the Efficacy and Safety of a Panthenol-Enriched Mask for Skin Barrier Recovery After Facial Laser Treatment — Gao et al., 2025
• ScienceDirect Topics: Panthenol — Overview
• Wikipedia: Pantothenic Acid
• PMC: Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy — Mechanism of Action and CoA Synthesis Pathway